NEU2: A Promising Drug Target for Neurodegenerative Diseases (G4759)

Target Name: NEU2

NCBI ID: G4759

NEU2

NEU2: A Promising Drug Target for Neurodegenerative Diseases

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are some of the most common and debilitating conditions affecting human beings. These diseases are characterized by the progressive loss of brain cells, leading to a wide range of symptoms such as memory loss, cognitive decline, and difficulty with daily activities.

One of the most promising drug targets in the fight against these diseases is NEU2 (MGC129579). NEU2 is a protein that is expressed in the brain and has been shown to play a role in the development and progression of neurodegenerative diseases.

The research on NEU2 began in the 1990s when a team of scientists at the National Institute on Mental Health (NIMH) identified the protein in the brain that was responsible for the production of a protein called neurofilament. This protein is thought to contribute to the build-up of tangled and toxic protein structures in the brain that are believed to cause the symptoms of neurodegenerative diseases.

Since then, researchers have been working to understand the role of NEU2 in the development and progression of neurodegenerative diseases. This has led to a number of exciting findings.

One of the key things that has been found is that NEU2 is involved in the production of the neurotransmitter dopamine. Dopamine is a chemical that is responsible for transmitting signals in the brain and is thought to play a key role in the development of Parkinson's disease.

Research has also shown that NEU2 is involved in the production of the neurotransmitter glutamate. Glutamate is another chemical that is involved in brain function and is thought to contribute to the development of neurodegenerative diseases.

In addition to its role in the production of neurotransmitters, NEU2 has also been shown to play a role in the regulation of the blood-brain barrier. The blood-brain barrier is a barrier that separates the brain from the blood and helps to protect it from harmful substances. However, researchers have found that the blood-brain barrier is often broken in neurodegenerative diseases, and that this can allow harmful substances to enter the brain. NEU2 has been shown to help regulate this barrier, which may be important for the development and progression of neurodegenerative diseases.

Another study has also shown that NEU2 may be involved in the development of neurodegenerative diseases by contributing to the formation of toxic protein structures in the brain. These structures, known as neurofilaments, have been found to be a hallmark of neurodegenerative diseases and are thought to contribute to the progressive loss of brain cells.

In conclusion, the research on NEU2 has been incredibly promising in the fight against neurodegenerative diseases. NEU2 has been shown to play a key role in the production of neurotransmitters, the regulation of the blood-brain barrier, and the formation of toxic protein structures in the brain. These findings suggest that NEU2 may be an attractive drug target for the development of new treatments for neurodegenerative diseases.

Protein Name: Neuraminidase 2

Functions: Exo-alpha-sialidase that catalyzes the hydrolytic cleavage of the terminal sialic acid (N-acetylneuraminic acid, Neu5Ac) of a glycan moiety in the catabolism of glycolipids, glycoproteins and oligosacharides (PubMed:14613940, PubMed:22228546). Recognizes sialyl linkage positions of the glycan moiety as well as the supramolecular organization of the sialoglycoconjugate. Displays preference for alpha-(2->3)-sialylated GD1a and GT1B gangliosides over alpha-(2->8)-sialylated GD1b, in both monomeric forms and micelles. Hydrolyzes monomeric GM1 ganglioside, but has no activity toward the miscellar form (PubMed:14613940). Has lower sialidase activity for glycoproteins such as fetuin and TF/transferrin that carry a mixture of alpha-(2->3) and alpha-(2->6)-sialyl linkages. Cleaves milk oligosaccharide alpha-(2->3)-sialyllactose, but is inactive toward alpha-(2->6)-sialyllactose isomer. Has no activity toward colominic acid, a homomer of alpha-(2->8)-linked Neu5Ac residues (PubMed:14613940)

The "NEU2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NEU2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets